159 related articles for article (PubMed ID: 32751805)
1. Concurrent
Malarikova D; Berkova A; Obr A; Blahovcova P; Svaton M; Forsterova K; Kriegova E; Prihodova E; Pavlistova L; Petrackova A; Zemanova Z; Trneny M; Klener P
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751805
[TBL] [Abstract][Full Text] [Related]
2. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
[TBL] [Abstract][Full Text] [Related]
3. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
4.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
5. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma.
Gaudio F; Dicataldo M; Di Giovanni F; Cazzato G; d'Amati A; Perrone T; Masciopinto P; Laddaga FE; Musto P; Maiorano E; Ingravallo G
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):599-605. PubMed ID: 37147150
[TBL] [Abstract][Full Text] [Related]
7. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
8. TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes.
Wang P; Wang F; He H; Chen Y; Lin H; Chen P; Chen X; Liu S
Ann Transl Med; 2021 Aug; 9(16):1330. PubMed ID: 34532467
[TBL] [Abstract][Full Text] [Related]
9. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
Karolová J; Kazantsev D; Svatoň M; Tušková L; Forsterová K; Maláriková D; Benešová K; Heizer T; Dolníková A; Klánová M; Winkovska L; Svobodová K; Hojný J; Krkavcová E; Froňková E; Zemanová Z; Trněný M; Klener P
Am J Hematol; 2023 Oct; 98(10):1627-1636. PubMed ID: 37605345
[TBL] [Abstract][Full Text] [Related]
10. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
[TBL] [Abstract][Full Text] [Related]
12. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
13. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
14. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape and prognostic analysis of mantle cell lymphoma.
Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
[TBL] [Abstract][Full Text] [Related]
17. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.
Jardin F; Picquenot JM; Parmentier F; Ruminy P; Cornic M; Penther D; Bertrand P; Lanic H; Cassuto O; Humbrecht C; Lemasle E; Wautier A; Bastard C; Tilly H
Br J Haematol; 2009 Sep; 146(6):607-18. PubMed ID: 19594747
[TBL] [Abstract][Full Text] [Related]
18. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
Greiner TC; Dasgupta C; Ho VV; Weisenburger DD; Smith LM; Lynch JC; Vose JM; Fu K; Armitage JO; Braziel RM; Campo E; Delabie J; Gascoyne RD; Jaffe ES; Muller-Hermelink HK; Ott G; Rosenwald A; Staudt LM; Im MY; Karaman MW; Pike BL; Chan WC; Hacia JG
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2352-7. PubMed ID: 16461462
[TBL] [Abstract][Full Text] [Related]
19. An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.
Inamdar AA; Loo A; Mikhail N; Lee P
Cureus; 2021 Aug; 13(8):e17598. PubMed ID: 34646650
[TBL] [Abstract][Full Text] [Related]
20. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
